Core Viewpoint - Eli Lilly and Company is set to report its first-quarter earnings on May 1, with sales and earnings estimates at $12.62 billion and $3.52 per share, respectively. However, earnings estimates for 2025 have seen a decline from $23.53 to $22.43 per share over the past month [1][4]. Earnings Performance - The company has had a mixed earnings performance, exceeding expectations in three of the last four quarters, with an average earnings surprise of 8.47% [2][3]. Earnings Estimates and Trends - Current earnings estimates for Q1, Q2, 2025, and 2026 are $3.52, $5.58, $22.43, and $31.15 per share, respectively. Notably, the earnings estimate for Q1 has decreased by 22.30% over the past month [1][4]. Factors Influencing Upcoming Results - Top-line growth in Q1 is expected to be driven by demand for FDA-approved tirzepatide medicines, specifically the diabetes drug Mounjaro and weight loss medicine Zepbound. However, sales of these drugs were below expectations in the latter half of 2024 due to slower growth and unfavorable channel dynamics [5][6]. Sales Estimates for Key Products - The Zacks Consensus Estimate for Mounjaro and Zepbound is $3.75 billion and $2.27 billion, respectively, while the company's estimates are $3.82 billion and $2.19 billion. Increased demand for other key growth drugs is also anticipated to support top-line growth [8][10]. Competitive Landscape - Sales of Trulicity are expected to decline due to competitive dynamics and lower realized prices in the U.S., with patient switches to Mounjaro impacting its performance [9][22]. The obesity market is becoming increasingly competitive, with several companies developing GLP-1-based candidates [23][24]. Stock Performance and Valuation - Lilly's stock has risen 14.8% year-to-date, outperforming the industry and the S&P 500 index. The stock is currently trading at a premium compared to the industry [13][16]. Investment Outlook - Despite challenges, including declining sales of key products and increasing competition, the company is viewed as having robust growth prospects, particularly with new product launches and expansions planned for 2025 [20][25].

Core Viewpoint - Eli Lilly And Co (NYSE: LLY) has experienced a double downgrade from HSBC, with a price target cut, raising concerns about competition and valuation [1] Group 1: Stock Performance - Eli Lilly's stock is currently trading at $870.31, down 1.6% following the downgrade [1] - Despite the recent decline, the stock has a year-to-date gain of 12.8% and is trading above the 200-day moving average [2] Group 2: Analyst Ratings - Prior to the downgrade, 22 out of 25 analysts had a "buy" or better rating on the stock, with a 12-month consensus target price of $998.05, indicating a 14.3% premium to current levels [1] Group 3: Options Market Sentiment - Short-term options traders are showing bearish sentiment, as indicated by a Schaeffer's put/call open interest ratio (SOIR) of 1.13, which is in the 95th percentile of the past 12 months [3]

Core Viewpoint - Eli Lilly and Company is set to report its first-quarter earnings on May 1, with sales and earnings estimates at $12.62 billion and $3.52 per share respectively, while earnings estimates for 2025 have seen a decline from $23.53 to $22.43 per share over the past month [1][4]. Earnings Performance - The company has exceeded earnings expectations in three of the last four quarters, with an average earnings surprise of 8.47% [2][3]. - The last reported quarter showed an earnings surprise of 5.77% [2]. Earnings Estimates and Trends - Current earnings estimates for Q1, Q2, 2025, and 2026 are $3.52, $5.58, $22.43, and $31.15 respectively, with a notable decline in Q1 estimates from $4.64 to $3.52 over the past 30 days, reflecting a -22.30% revision [1][4]. Factors Influencing Upcoming Results - Top-line growth in Q1 is expected to be driven by demand for FDA-approved tirzepatide medicines, specifically diabetes drug Mounjaro and weight loss medicine Zepbound [5]. - Sales of Mounjaro and Zepbound were below expectations in the latter half of 2024, attributed to slower growth and unfavorable channel dynamics [5][6]. - The FDA's approval of Zepbound for moderate-to-severe obstructive sleep apnea is anticipated to contribute positively to sales [7]. Sales Estimates for Key Products - The Zacks Consensus Estimate for Mounjaro and Zepbound is $3.75 billion and $2.27 billion respectively, while internal estimates are $3.82 billion and $2.19 billion [8]. - Sales estimates for other drugs include Trulicity at $1.11 billion, Taltz at $663 million, Verzenio at $1.25 billion, Jardiance at $675 million, Olumiant at $228 million, and Emgality at $220 million [10]. Competitive Landscape - Lilly faces competition in the diabetes and obesity market, particularly from Novo Nordisk's Wegovy, with several companies developing GLP-1-based candidates that could threaten market dominance [22][23]. - Despite competition, Lilly is investing in obesity treatments and has new molecules in clinical development, including a promising oral GLP-1 agonist [24]. Stock Performance and Valuation - Lilly's stock has increased by 14.8% this year, outperforming the industry average of 1.5% [13]. - The stock is currently trading at a premium compared to the industry [16]. Investment Outlook - Despite challenges, Lilly is viewed as a strong investment due to its robust growth prospects and position as a leading drugmaker [25].

Market Overview - US stock index futures are all down before the market opens, with Dow futures down 0.06%, S&P 500 futures down 0.12%, and Nasdaq futures down 0.07% [1] - Major European indices show positive performance, with Germany's DAX up 0.52%, UK's FTSE 100 up 0.11%, France's CAC40 up 0.72%, and the Euro Stoxx 50 up 0.50% [2][3] - WTI crude oil is down 0.33% at $62.81 per barrel, while Brent crude oil is down 0.36% at $65.56 per barrel [3][4] Economic Data and Corporate Earnings - The upcoming week is significant for economic data and corporate earnings, with the April non-farm payroll report and Q1 inflation data being key focuses [5] - 180 S&P 500 companies are set to report quarterly earnings, with major companies like Apple, Amazon, Coca-Cola, Eli Lilly, Meta, Microsoft, and Chevron in the spotlight [5] Corporate Actions - Spirit AeroSystems has reached an agreement with Airbus for the acquisition of certain assets, with Boeing repurchasing its previously divested business for $4.7 billion in stock [8] - Merck has announced a $3.9 billion acquisition of SpringWorks Therapeutics to enhance its oncology drug portfolio, with the deal valued at approximately $3.4 billion in enterprise value [9] - Amazon has seen prices of nearly 1,000 products rise by an average of 30% due to the impact of tariffs, affecting various categories from electronics to clothing [10] Earnings Forecast - Upcoming earnings reports include companies such as NXP Semiconductors, AstraZeneca, BP, Novartis, Deutsche Bank, HSBC, Coca-Cola, Pfizer, UPS, General Motors, Daqo New Energy, and JinkoSolar [11]

本文约 2 5 0 0 字，推荐阅读时长 1 5 分钟，欢迎关注新财富公众号。 1 引言 4月14日，美国商务部宣布启动对进口药品的国家安全调查。这一调查覆盖了所有进口药品，包括成 品仿制药、原研药以及用于生产这些药品的关键药用成分。此举属于特朗普政府根据1962年《贸易扩 展法》第232条对多个行业进行的关税调查的一部分。虽然调查尚未结束，预计结果将在270天内公 布，但业内普遍认为，这将赋予特朗普政府对进口药品和原料药征收关税的权力。特别是对中国等主 要药品出口国的影响，可能会带来严重的供应链中断及成本上升。 事实上，美国每年从中国进口药品总额约60亿美元，其中大量为抗生素、抗病毒及心血管药物等基础 药物。一旦关税进一步扩大实施，这些进口药品的成本预计将明显上升，对美国本土药品生产商带来 直接冲击。为应对这种风险，特朗普政府提出多项措施推动产业本土化。 分析师预计，如果对来自中国的API征收10%的关税，仿制药企业的利润将下跌2%-3%，创新药利润 下跌可能更严重。 2 美国关税筑墙， 中概股 跌宕 自2025年特朗普重新执政以来，美国政府出台了一系列针对生物医药产业的重要政策，核心目标是强 化美国医药产 ...

见闻历 . 每天多看我一眼，投资赚的多一点。 | 见闻财经日历 | | | ▼ 华尔街见闻 | | --- | --- | --- | --- | | WSCN Economic Calendar | | | | | 时间 | 地区 | 内容 | 预期 前値 | | 4月28日 周一 | | | | | 事件 | 国内 | 待定 十四届全国人大常委会第十五次会议4月27日至 30日在北京举行 | | | 酒外 | | 待定 加拿大大选正式投票日 | | | 国内 | | 海天味业、昆仑万维、传音控股、药明康德、青岛啤酒 京东方A、上海电气、迈瑞医疗、恒立液压、保利发展 | | | | | 中国石化、张小泉、中国建筑、顺丰控股、宁沪高速 | | | 财报 | | 老板电器、百济神州-U、华帝股份 | | | 滝外 | | 达美乐披萨、恩智浦 | | | 4月29日 周二 | | | | | 事件 | 酒外 | 待定 日本股市因昭和日休市一日 | | | 滝 | | Meta首届开源Al大会 | | | 财报 | 国内 | 光明乳业、工商银行、海尔智家、贵州茅台 万科A、长江电力、通威股份、伊利股份、金龙鱼 韦尔 ...

医药生物 2025 年 04 月 26 日 相关研究报告 《Bima 联合司美的数据将在 ADA 大 会读出，减重进入高质量时代—行业 周报》-2025.4.20 《推荐科研服务板块国产替代的机会 —行业周报》-2025.4.13 《关注优化药品集采下的投资机会— 行业周报》-2025.4.6 Orforglipron 产业链被低估，国内相关公司有望长周 期受益 ——行业点评报告 | 余汝意（分析师） | 汪晋（联系人） | | --- | --- | | yuruyi@kysec.cn | wangjin3@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790123050021 | wangjin3@kysec.cn 证书编号：S0790123050021 投资评级：看好（维持） 行业走势图 数据来源：聚源 -19% -10% 0% 10% 19% 29% 2024-04 2024-08 2024-12 医药生物 沪深300 开 源 证 请务必参阅正文后面的信息披露和法律声明 1 / 8 首个小分子口服 GLP-1RA 药物 3 期临床研究成功 2025 年 4 月 1 ...

Core Insights - The article discusses the author's extensive background in biomedicine and bioengineering, emphasizing over 20 years of experience in the research and development of novel Cell & Gene Therapies (CGT) aimed at addressing various clinical needs [1] - The author aims to leverage their expertise in life sciences to evaluate the potential of innovative treatments, particularly those utilizing CGT, and their ability to generate shareholder returns [1] Group 1 - The author has a Master of Science in Biomedicine and a PhD in Bioengineering, highlighting a strong academic foundation in relevant fields [1] - The focus will be on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, providing insights into company performance and market potential [1] Group 2 - The author is associated with another contributor but emphasizes independent work and adherence to guidelines [1] - There is a clear statement of no current stock or derivative positions in the companies mentioned, indicating an unbiased perspective [2]

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings est ...

Market Overview - Major U.S. stock index futures are down, with Dow futures falling by 0.75%, S&P 500 futures down by 0.64%, and Nasdaq futures decreasing by 0.89% [1] - Technology stocks are experiencing a broad decline, with Apple down by 1.31%, Nvidia down by 1.68%, and Amazon down by 1.08% [1] Company-Specific News - Tesla's stock price target has been lowered by HSBC from $125 to $120, maintaining a "reduce" rating. The analyst cites aging product lineup, increased competition in China, the U.S., and Europe, and brand image issues as negative factors affecting Tesla's performance and future outlook. Tesla's stock is down by 1.71% [1] - Eli Lilly has filed lawsuits against four generic drug manufacturers for allegedly producing and selling unapproved generic versions of its weight loss and diabetes medications. A U.S. judge previously prohibited these manufacturers from producing such generics. Eli Lilly's stock is down by 0.64% [1] - Southwest Airlines announced plans to cut flights in the second half of the year due to declining domestic booking trends and will not reaffirm its profit guidance for 2025 and 2026. The stock is down by 2.82% [2] - IBM's stock fell by over 8% after the cancellation of 15 government contracts due to cost-cutting measures by the Department of Government Efficiency (DOGE), despite reporting better-than-expected earnings and revenue for Q1 2025 [2] - Morgan Stanley raised the stock price target for AT&T from $28 to $31, maintaining an "overweight" rating, following AT&T's Q1 2025 earnings report that exceeded expectations and the announcement of a $10 billion stock buyback plan [2] - Sanofi's Q1 revenue of $9.89 billion fell short of the expected $10.99 billion, leading to a decline in its stock by 1.04% [3] - Texas Instruments reported Q1 earnings per share of $1.28, surpassing the expected $1.06, with revenue of $4.1 billion exceeding the anticipated $3.91 billion. The stock rose by 4.04% [3]